Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1155 | 1155 | 1255 | 1094 | 1677 | 2995 |
Fund Return | 15.47% | 15.47% | 25.49% | 3.04% | 10.89% | 11.59% |
Place in category | 41 | 41 | 57 | 60 | 49 | 11 |
% in Category | 51 | 51 | 77 | 91 | 81 | 26 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
MUKAM eMAXIS Slim US Equity S&P 500 | 4,220.69B | 23.30 | 23.20 | - | ||
MUKAM eMAXIS Slim All World Equity | 3,088.73B | 19.62 | 19.70 | - | ||
Slim Developed Countries Eq Index | 701.78B | 20.71 | 21.91 | - | ||
MUKAM MUFJ Prime Balance Stable Gro | 331.5B | 8.39 | 7.77 | 6.40 | ||
MUKAM Morgan Stanley Global Premium | 316.81B | 11.40 | 16.81 | 13.05 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fidelity Japan Growth Equity Fund | 549.64B | 14.08 | 8.13 | 10.05 | ||
Sparx New International Blue Chip J | 214.95B | 24.65 | 12.04 | 14.97 | ||
SMDS SMBC Wrap Japan Growth Equity | 73.38B | 7.23 | 2.65 | 7.65 | ||
Capital Japan Equity Fund | 67.99B | 13.45 | 9.76 | 9.40 | ||
Fidelity Japan Open | 64.49B | 14.36 | 8.82 | 10.52 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Nxera Pharma | JP3431300007 | 4.15 | 1,460.0 | -2.47% | |
Daiichi Sankyo | JP3475350009 | 3.98 | 5,003.0 | +5.12% | |
Sony | JP3435000009 | 3.94 | 12,765.0 | +0.08% | |
Sansan | JP3332540008 | 3.84 | 1,467.0 | +1.73% | |
Asahi Intecc | JP3110650003 | 3.40 | 2,247.5 | -1.75% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Buy | Strong Buy |
Technical Indicators | Strong Sell | Sell | Strong Buy |
Summary | Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review